#UK Jaws drop as dogfish shark steroid points to Parkinson’s treatment

//

Professor Chris Dobson University of Cambridge

Cambridge scientists believe that a steroid discovered in the 1990s in dogfish sharks could lead to potential treatments for Parkinson’s Disease.

Initial research suggest that squalamine could be exploited in various ways as the basis of a new therapeutic. 

The compound has previously been used in clinical trials for cancer and eye conditions in the US and a trial in Parkinson’s Disease patients is now being planned by one of the researchers involved in the study.

While squalamine was discovered in dogfish sharks it is impossible to derive any medical benefits from shark tissue and the form used by scientists is a safer and more reliable synthetic analogue. To date, it has been extensively investigated as a potential anti-infective and anticancer therapy.

But in the new study, researchers discovered that squalamine also dramatically inhibits the early formation of toxic aggregates of the protein alpha-synuclein – a process thought to start a chain reaction of molecular events eventually leading to Parkinson’s. They also found that it can suppress the toxicity of these poisonous particles.

While their findings only represent a step towards a treatment for Parkinson’s Disease in humans, they described the results as representing significant progress.

The study was led by academics from the Centre for Misfolding Diseases, based in the Chemistry Department at the University of Cambridge, UK, and Georgetown University and the National Institutes of Health in the United States. Scientists from the Netherlands, Italy and Spain also played key roles.

The researchers tested squalamine in both cell cultures in the lab, and in an animal model using nematode worms. While their findings therefore only represent a step towards a treatment for Parkinson’s Disease in humans, they described the results as representing significant progress.

The findings are published in Proceedings of The National Academy of Sciences.

Professor Christopher Dobson, one of the authors and a Professor in the Chemistry Department at the University of Cambridge, said: “To our surprise, we found evidence that squalamine not only slows down the formation of the toxins associated with Parkinson’s Disease, but also makes them less toxic altogether.”

“If further tests prove to be successful, it is possible that a drug treating at least some of the symptoms of Parkinson’s Disease could be developed from squalamine. We might then be able to improve on that incrementally, by searching for better molecules that augment its effects.”

Co-author, Professor Michele Vendruscolo, from the Department of Chemistry at the University of Cambridge added: “Squalamine can prevent alpha-synuclein from malfunctioning, essentially by normalising its binding to lipid membranes. If there are going to be ways to beat the disease, it seems likely that this is one that may work.”

The study stemmed from research led by Dr Michael Zasloff, professor of surgery and pediatrics at Georgetown University School of Medicine in the US. Zasloff, who also co-authored the latest study, discovered squalamine in 1993 and has since led extensive work exploring its potential as a treatment for conditions including cancer.

In the new study, researchers explored squalamine’s capacity to displace alpha-synuclein from cell membranes – a phenomenon that was first observed in the laboratory headed by another co-author, Dr Ad Bax, in the National Institutes of Health in Bethesda, USA. This finding has significant implications for Parkinson’s Disease, as alpha-synuclein works by binding to the membranes of tiny, bubble-like structures called synaptic vesicles, which help to transfer neurotransmitters between neurons.

Under normal circumstances, the protein aids the effective flow of chemical signals, but in some instances, it malfunctions and instead begins to clump together, creating toxic particles harmful to brain cells. This clustering is the hallmark of Parkinson’s Disease.

The researchers carried out a series of experiments which analysed the interaction between squalamine, alpha-synuclein and lipid vesicles, building on earlier work from Cambridge scientists which showed the vital role that vesicles play in initiating the aggregation. They found that squalamine inhibits the aggregation of the protein by competing for binding sites on the surfaces of synthetic vesicles. By displacing the protein in this way, it significantly reduces the rate at which toxic particles form.

Further tests, carried out with human neuronal cells, revealed  that squalamine also suppresses the toxicity of these particles.

Finally, the group tested the impact of squalamine in an animal model of Parkinson’s Disease, by using nematode worms genetically programmed to over-express alpha-synuclein in their muscle cells. As the worms develop, alpha-synuclein aggregation causes them to become paralysed, but squalamine prevented the paralysis from taking effect. 

“We could literally see that the oral treatment of squalamine did not allow alpha-synuclein to cluster, and prevented muscular paralysis inside the worms,” Zasloff said.

Zasloff is now planning a clinical trial with squalamine in Parkinson’s Disease patients in the US.

Further research is needed to determine the precise benefits of squalamine – and what form any resulting drug might take. It is not yet clear whether squalamine can reach the specific regions of the brain where the main molecular processes determining Parkinson’s Disease take place.

The researchers suggest it would be interesting to start investigating the efficacy of squalamine as a means to alleviate certain symptoms. If taken orally, for instance, they believe the compound could relieve the severe constipation many patients experience, by targeting the gastrointestinal system and affecting alpha-synuclein in the gut. A treatment of that sort could “cascade” signals to other parts of the body.

“Targeting alpha-synuclein in the gut may perhaps in some cases be sufficient to delay the progress of other aspects of Parkinson’s Disease, at least for symptoms concerning the peripheral nervous system,” Vendruscolo said.

“In many ways squalamine gives us a lead rather than a definitive treatment,” Professor Dobson added: “Parkinson’s Disease has many symptoms and we hope that either this compound, or a derivative of it with a similar mechanism of action, could alleviate at least some of them. One of the most exciting prospects is that, subject to further tests, we might be able to use it to make improvements to patients’ lives, while also studying other compounds with the aim of developing a more powerful treatment in the future.”

• PHOTOGRAPH SHOWS: Professor Christopher Dobson

from Business Weekly http://ift.tt/2jpKNKl

This entry was posted in #UK by Startup365. Bookmark the permalink.

About Startup365

Chaque jour nous vous présenterons une nouvelle Startup française ! Notre pays regorge de talents et d'entrepreneurs brillants ! Alors partons à la découverte des meilleures startup françaises ! Certaines d'entre elles sont dans une étape essentielle dans la vie d'une startup : la recherche de financement, notamment par le financement participatif (ou crowdfunding en anglais). Alors participez à cette grande aventure en leur faisant une petite donation ! Les startups françaises ont besoin de vous !